Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Yong Huo(Sun Yat-sen University), Lei Qian, Beijian Chen(Heze Municipal Hospital), Lipeng Li(Third People 's Hospital of Liaoyang), Huan Deng(Nanfang Hospital), Lijuan Pei, Guanzhong Zheng(Peking University), Haoyu Li(Qingdao University), Li Li(China Pharmaceutical University), Lu Liu(Qiqihar Medical University), Ying Xie(The First Hospital of Kunming), Pei An(Peking University), Fengtai Xue, Di Lu(China National Petroleum Corporation (China)), Yuan Ji(Jinan University), Yanling Qu(Yuncheng University), Xinchun Yang(Beijing Chaoyang Emergency Medical Center), Xiufang Gao(Huashan Hospital), Shuqing Wang(Qiqihar Medical University), Qiufang Lian(Xianyang Normal University), Guotian Yin(Henan Medical University), Wenjun Huang(Lishui Central Hospital)
The Lancet Regional Health - Western Pacific
September 28, 2023
10.1016/j.lanwpc.2023.100907
Cited by 28

Related Papers

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china
|Annals of Neurology|2011|507
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
|Thrombosis and Haemostasis|2020|334